Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Updates from the Phase II AERN trial: nivolumab and radiotherapy for the treatment of R/R HL

Paul Jan Bröckelmann • 10 Jun 2022
EHA 2022
Hodgkin Lymphoma Lymphoma Antibodies Nivolumab
AERN

Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, shares some updates from the Phase II AERN trial (NCT03480334) evaluating the use of nivolumab and radiotherapy for the treatment of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have failed prior anti-PD1 treatment. Dr Bröckelmann highlights some results from this trial, drawing focus on the abscopal effect of this treatment approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Paul Jan Bröckelmann

The growing role of anti-PD1 inhibitors in the frontline treatment of HL
2:32
The growing role of anti-PD1 inhibitors in the frontline treatment of HL
Paul Jan Bröckelmann • 17 Oct 2022
The importance of individualizing treatment approaches in HL to improve patient outcomes
2:04
The importance of individualizing treatment approaches in HL to improve patient outcomes
Paul Jan Bröckelmann • 17 Oct 2022
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
2:27
Using Hodgkin lymphoma as a model for immuno-oncologic therapeutic approaches in other lymphomas
Paul Jan Bröckelmann • 17 Oct 2022
Recent clinical developments in the treatment landscape for older patients with HL
2:17
Recent clinical developments in the treatment landscape for older patients with HL
Paul Jan Bröckelmann • 17 Oct 2022

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals